Senators slam Pfizer-PBM deal to blunt generic Lipitor

Share this article:
Poll: statin use will grow modestly
Poll: statin use will grow modestly
Pfizer's Lipitor had not yet gone off patent before a trio of Senate healthcare heavyweights was firing off letters to the drugmaker assailing its efforts to conserve Lipitor share through a deal with pharmaceutical benefit managers.

“We are concernced that arrangements like this will hinder access to generic drugs today and in the future,” Sens. Herb Kohl, Max Baucus and Chuck Grassley wrote in a Nov. 30 letter addressed to Pfizer's Ian Read, citing a Nov. 11 New York Times article that said a Pfizer deal with major PBMs would offer discounts in exchange for prescribing patients the branded version instead of the generic.

Pfizer said in a statement that the article “contained incomplete and incorrect information about our Lipitor programs,” arguing that the point of the offer is to make Lipitor available at or below generic prices for the 180-day period and that participation by health plans “is entirely voluntary.”

“We are concerned that the PBMs may charge health plan sponsors, including employers and Medicare Part D, full price for brand name Lipitor” through May 31 “while pocketing the discount from Pfizer.” The Senators noted that over the next four years, branded drugs worth about $100 million in US sales will lose patient protection.

“This heightens our concern that these types of arrangements will become a trend,” said the Senators, “ultimately compromising access to generic drugs and increasing overall healthcare costs.”

In addition to Pfizer, the Senators sent similar letters to five PBMs, including CatalystRx, Medco, Coventry, Express Scripts and UnitedHealth Group.

In addition to Watson's authorized generic atorvastatin, which is already on the market, Ranbaxy is launching a generic competitor to the $10 billion branded drug, which lost patent protection at the end of November, through a deal with Teva that got the FDA's blessing this morning.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...